Prescription medicine
Tranylcypromine Brand names: Parnate
Tranylcypromine (Parnate) is a prescription medicine with an FDA approval on record since 1961. FDA's NDC Directory lists it from 4 generic labelers, and pharmacies paid $0.591 per tranylcypromine sulf 10 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- A presentation discontinued
- Boxed warning
Check it at the source: the tranylcypromine FDA label on DailyMed (effective July 2, 2025, Advanz Pharma (US) Corp.); the NDA 12342 record on Drugs@FDA; every tranylcypromine label on DailyMed.
Highlights of the record
FDA label of July 2, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
SUICIDAL THOUGHTS AND.
BEHAVIORS and HYPERTENSIVE CRISIS WITH SIGNIFICANT TYRAMINE USE Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [ see Warnings and Precautions (5.1) ]. PARNATE is not approved for use in pediatric patients [ see Use in Specific Populations (8.4) ]. Hypertensive Crisis with Significant Tyramine Use Excessive consumption of foods or beverages with significant tyramine content or the use of certain drugs with PARNATE or after PARNATE discontinuation can precipitate hypertensive crisis. Monitor blood pressure and allow for medication-free intervals between administration of PARNATE and interacting drugs. Instruct patients to avoid ingestion of foods and beverages with high tyramine content [ see Warnings and Precautions (5.2) and Drug Interactions ( 7.1 , 7.2 )]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS AND HYPERTENSIVE CRISIS WITH SIGNIFICANT TYRAMINE USE See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. […]
Used for
From the label: indications and usagePARNATE is indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants.
Forms and strengths
- 10 mg
Tablet; film-coated tablet.
On the market
- Earliest approval on file
- February 21, 1961 Parnate, Advanz Pharma; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 3 first June 29, 2006; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 6 of which 4 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.591 per tablet Tranylcypromine sulf 10 mg tablet
- Shortage (FDA)
- None current 1 past records
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,118 through July 30, 2026
What is tranylcypromine used for?
From the label: indications and usagePARNATE is indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants. PARNATE is not indicated for the initial treatment of MDD due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [ see Contraindications (4), Warnings and Precautions (5), and Drug Interactions (7) ]. […]
Conditions named in the indications of tranylcypromine's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Monoamine Oxidase Inhibitor.
Source: FDA drug label (PARNATE), Advanz Pharma (US) Corp., effective July 2, 2025 (SPL set b72d8187-dfcc-4ea0-b5e9-c0be95b69a27), via openFDA; the full label on DailyMed
What does the patient leaflet for tranylcypromine say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about PARNATE?PARNATE can cause serious side effects including: Increase in suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment and when the PARNATE dose is changed. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have, or have a family history of, bipolar illness (also called manic-depressive illness) or suicidal thoughts or actions. PARNATE is not for use in children. How can I watch for and try to prevent suicidal thoughts and actions? Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed. Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms Call a healthcare provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempts to commit suicide new or worse depression new or worse anxiety feeling agitated, restless, angry or irritable panic attacks trouble sleeping new or worse irritability acting aggressive, being angry or violent acting on dangerous impulses an extreme increase in activity or talking (mania) other unusual changes in behavior or mood A sudden, severe increase in blood pressure (hypertensive crisis). […]
From the patient leaflet: What should I avoid while taking PARNATE?Do not eat foods or have drinks that have high amounts of tyramine while taking PARNATE or for 2 weeks after you stop taking PARNATE. All foods you eat should be fresh or properly frozen. Avoid foods when you do not know how those foods should be stored. Ask your healthcare provider if you are not sure if certain foods and drinks contain tyramine. The table below lists some of the foods and drinks you should avoid while you take PARNATE. Type of Food and Drink that contain Tyramine Meat, Poultry, and Fish air dried, aged and fermented meats, sausages, and salamis pickled herring any spoiled or improperly stored meat, poultry, and fish. […]
Source: FDA drug label (PARNATE), Advanz Pharma (US) Corp., effective July 2, 2025 (SPL set b72d8187-dfcc-4ea0-b5e9-c0be95b69a27), via openFDA; the full label on DailyMed
Is there a generic for tranylcypromine (Parnate)?
The FDA approved the first generic tranylcypromine on June 29, 2006. 3 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists tranylcypromine from 4 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1961 earliest approval on file
- 2006 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for tranylcypromine (Parnate)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.591 per Tranylcypromine sulf 10 mg tablet, down 12% from $0.669 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Tranylcypromine sulf 10 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Tranylcypromine sulf 10 mg tablet | Generic | $0.591 per tablet | $17.73 | -12% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is tranylcypromine in shortage?
No tranylcypromine presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 1 record is all marked to be discontinued, the latest updated October 21, 2025. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Parnate, Tablet, 10 mg (NDC 0591-5590-01) | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | October 21, 2025 |
Every tranylcypromine presentation in the FDA shortage database
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
What does the tranylcypromine label say about other medicines?
The tranylcypromine label names 38 other medicines in its interaction, contraindication or warning sections. The labels of 41 other medicines name tranylcypromine. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Amoxapine | boxed warning | … serotonin and norepinephrine reuptake inhibitors (SNRIs) tricyclic antidepressants other antidepressants, such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such as … |
| Anhydrous citric acid | boxed warning | What are the ingredients in PARNATE? Active Ingredient: tranylcypromine sulfate Inactive Ingredients: microcrystalline cellulose, anhydrous citric acid, croscarmellose sodium, D&C Red No. 7, FD&C Blue No. 2, FD&C Yellow No. … |
| Bupropion | boxed warning | … norepinephrine reuptake inhibitors (SNRIs) tricyclic antidepressants other antidepressants, such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such as pseudoephedrine … |
| Buspirone | boxed warning | These medicines are in some cold, hay fever or weight-loss medicines. sympathomimetic herbal medicines or dietary supplements antihistamines (allergy medicines) triptans buspirone carbamazepine dextromethorphan dopamine hydroxytryptophan and tryptophan levodopa and methyldopa meperidine rasagline resperine … |
| Caffeine | drug interactions | Class of Food or Beverage: Beverages; Tyramine-Rich Foods and Beverages to Avoid: All varieties of tap beer and beers that have not been pasteurized so as to allow for ongoing fermentation and excessive amounts of caffeine.; … |
| Carbamazepine | boxed warning | These medicines are in some cold, hay fever or weight-loss medicines. sympathomimetic herbal medicines or dietary supplements antihistamines (allergy medicines) triptans buspirone carbamazepine dextromethorphan dopamine hydroxytryptophan and tryptophan levodopa and methyldopa meperidine rasagline resperine … |
| Chlorpromazine | drug interactions | Product: Chlorpromazine; Clinical Comment on Concomitant Use a: Use with caution d; Predominant Effect/Risk [Hypertensive Reaction (HR) b or Serotonin Syndrome (SS) c ]: Hypotensive effects e |
| Cyclobenzaprine | contraindications | cyclobenzaprine; methyldopa; tetrabenazine |
| Dextromethorphan | boxed warning | These medicines are in some cold, hay fever or weight-loss medicines. sympathomimetic herbal medicines or dietary supplements antihistamines (allergy medicines) triptans buspirone carbamazepine dextromethorphan dopamine hydroxytryptophan and tryptophan levodopa and methyldopa meperidine rasagline resperine … |
| Droperidol | drug interactions | Product: Droperidol; Clinical Comment on Concomitant Use a: Use with caution d; Predominant Effect/Risk [Hypertensive Reaction (HR) b or Serotonin Syndrome (SS) c ]: QT interval prolongation |
| Entacapone | drug interactions | Product: Entacapone; Clinical Comment on Concomitant Use a: Use with caution d; Predominant Effect/Risk [Hypertensive Reaction (HR) b or Serotonin Syndrome (SS) c ]: HR |
| Ephedrine | boxed warning | … amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such as pseudoephedrine, phenylephrine and ephedrine. |
| Epinephrine | drug interactions | If in the absence of therapeutic alternatives and emergency treatment with a contraindicated drug (e.g., linezolid, intravenous methylene blue, direct-acting sympathomimetic drugs such as epinephrine) becomes necessary and cannot be delayed, discontinue PARNATE as soon as possible before initiating treatment with the … |
| Fentanyl | drug interactions | Product: Fentanyl; Clinical Comment on Concomitant Use a: Use with caution d; Predominant Effect/Risk [Hypertensive Reaction (HR) b or Serotonin Syndrome (SS) c ]: SS |
Every other medicine the tranylcypromine label names
| Medicine named | Section | What the label says |
|---|---|---|
| Fluoxetine | drug interactions | This period can be several weeks long (e.g., a minimum of 5 weeks for fluoxetine given fluoxetine's long half-life). |
| Levodopa | boxed warning | … carbamazepine dextromethorphan dopamine hydroxytryptophan and tryptophan levodopa and methyldopa meperidine rasagline resperine s-adenosyl-L-methionine (SAM-e) tapentadol tetrabenazine Ask your … |
| Linezolid | drug interactions | Product: Antidepressants including but not limited to: Other MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs) Selective serotonin reuptake inhibitors (SSRIs) and serotonin and … |
| Lithium | drug interactions | Product: Lithium; Clinical Comment on Concomitant Use a: Use with caution d; Predominant Effect/Risk [Hypertensive Reaction (HR) b or Serotonin Syndrome (SS) c ]: SS |
| Meperidine | boxed warning | … dopamine hydroxytryptophan and tryptophan levodopa and methyldopa meperidine rasagline resperine s-adenosyl-L-methionine (SAM-e) tapentadol tetrabenazine Ask your healthcare provider or pharmacist if … |
| Methadone | drug interactions | Product: Methadone; Clinical Comment on Concomitant Use a: Use with caution d; Predominant Effect/Risk [Hypertensive Reaction (HR) b or Serotonin Syndrome (SS) c ]: SS |
| Methyldopa | boxed warning | … dextromethorphan dopamine hydroxytryptophan and tryptophan levodopa and methyldopa meperidine rasagline resperine s-adenosyl-L-methionine (SAM-e) tapentadol tetrabenazine Ask your healthcare provider … |
| Methylene blue | drug interactions | Product: Antidepressants including but not limited to: Other MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs) Selective serotonin reuptake inhibitors (SSRIs) and serotonin and … |
| Metoclopramide | drug interactions | Product: Metoclopramide; Clinical Comment on Concomitant Use a: Use with caution d; Predominant Effect/Risk [Hypertensive Reaction (HR) b or Serotonin Syndrome (SS) c ]: HR/SS |
| Milnacipran | contraindications | dextromethorphan; milnacipran; tryptophan |
| Mirtazapine | drug interactions | Product: Mirtazapine; Clinical Comment on Concomitant Use a: Contraindicated a; Predominant Effect/Risk [Hypertensive Reaction (HR) b or Serotonin Syndrome (SS) c ]: SS |
| Nefazodone | boxed warning | … other antidepressants, such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure … |
| Oxcarbazepine | drug interactions | Product: Oxcarbazepine; Clinical Comment on Concomitant Use a: Use with caution d because of close structural relationship with tricyclic antidepressants; … |
| Phenylephrine | boxed warning | … blood pressure (sympathomimetic medicine), such as pseudoephedrine, phenylephrine and ephedrine. |
| Pseudoephedrine | boxed warning | … that can raise blood pressure (sympathomimetic medicine), such as pseudoephedrine, phenylephrine and ephedrine. |
| Rasagiline | contraindications | dopamine; rasagiline |
| Tapentadol | boxed warning | … methyldopa meperidine rasagline resperine s-adenosyl-L-methionine (SAM-e) tapentadol tetrabenazine Ask your healthcare provider or pharmacist if you are not sure if you take any of these medicines. … |
| Tetrabenazine | boxed warning | … meperidine rasagline resperine s-adenosyl-L-methionine (SAM-e) tapentadol tetrabenazine Ask your healthcare provider or pharmacist if you are not sure if you take any of these medicines. … |
| Titanium dioxide | boxed warning | … 2, FD&C Yellow No. 6, gelatin, lactose, magnesium stearate, talc, titanium dioxide, carnauba wax, polyethylene glycol 400 and 8000 and hypromellose Manufactured for: |
| Tolcapone | drug interactions | Product: Tolcapone; Clinical Comment on Concomitant Use a: Use with caution d; Predominant Effect/Risk [Hypertensive Reaction (HR) b or Serotonin Syndrome (SS) c ]: HR |
| Tramadol | drug interactions | Product: Tramadol; Clinical Comment on Concomitant Use a: Use with caution d; Predominant Effect/Risk [Hypertensive Reaction (HR) b or Serotonin Syndrome (SS) c ]: SS; Increased seizure risk |
| Trazodone | boxed warning | … antidepressants, such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic … |
| Vilazodone | boxed warning | … such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such … |
| Vortioxetine | boxed warning | … amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such as … |
Other labels that name tranylcypromine
Source: FDA drug label (PARNATE), Advanz Pharma (US) Corp., effective July 2, 2025 (SPL set b72d8187-dfcc-4ea0-b5e9-c0be95b69a27), via openFDA; the full label on DailyMed
What do FAERS reports show for tranylcypromine?
The FDA Adverse Event Reporting System holds 1,118 reports that list tranylcypromine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 89 are coded as a death and 328 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as tranylcypromine?
30 other medicines are given the same way (oral) and in the same FDA class as tranylcypromine or labeled mainly for the same use (depression), the same class first. Depression lists all 37 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Isocarboxazid | Depression | none listed | n/a | In shortage |
| Bupropion | Depression | 73 labelers | $0.0785 per tablet 150 mg tablet | No current entry |
| Venlafaxine | Depression | 62 labelers | $0.0799 per capsule 75 mg capsule | No current entry |
| Aripiprazole | Depression | 47 labelers | $0.110 per tablet 5 mg tablet | No current entry |
| Fluoxetine | Depression | 59 labelers | $0.0519 per capsule 40 mg capsule | No current entry |
| Sertraline | Depression | 48 labelers | $0.0507 per tablet 100 mg tablet | No current entry |
| Amitriptyline | Depression | 36 labelers | $0.03 per tablet 10 mg tablet | No current entry |
| Duloxetine | Depression | 45 labelers | $0.102 per capsule 30 mg capsule | No current entry |
Every medicine labeled for the same conditions as tranylcypromine
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to tranylcypromine
- 30 medicines for the same use
- Other MAO inhibitors
- the pharmacologic class, with prices and generics
- Tranylcypromine side effects
- the label's list beside FAERS reports
- Tranylcypromine shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other